公司资料
Akebia Therapeutics 股价、新闻与催化剂
- 股票代码:
- AKBA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.86 USD (-1.47%)
收盘价
最后更新: 2026年8月17日
251M USD
市值
股价为何变动
As of Aug 17, 2026, AKBA closed down 1.47% at $0.8600. No new same-company headline was identified in the current news window.
公司概览
Kidney-Disease Company
Akebia Therapeutics develops and commercializes medicines for people with kidney disease. Its portfolio combines an anemia franchise with clinical programs for rare and acute renal disorders.
Vafseo
Vafseo, or vadadustat, is an oral HIF prolyl-hydroxylase inhibitor for anemia due to chronic kidney disease in adults receiving dialysis. Akebia is conducting post-approval studies of alternative dosing and clinical outcomes.
Vafseo Evidence Program
The VOCAL Phase 3b study evaluates three-times-weekly Vafseo dosing, while the large Phase 4 VOICE study compares mortality and hospitalization outcomes with standard erythropoiesis-stimulating agents.
Praliciguat
Praliciguat is an oral soluble-guanylate-cyclase stimulator in Phase 2 testing for focal segmental glomerulosclerosis.
AKB-097
AKB-097 is preparing for a Phase 2 basket study in IgA nephropathy, lupus nephritis and C3 glomerulopathy.
AKB-9090
AKB-9090 is in Phase 1 development as a potential preventive treatment for cardiac-surgery-associated acute kidney injury.
未来催化剂
- Initiation of a Phase 2 basket study of AKB-097 in the second half of 2026.
- Topline Phase 3b VOCAL data in the fourth quarter of 2026.
- Topline Phase 1 data for AKB-9090 in early 2027.
- Initial Phase 2 data for AKB-097 in 2027.
- Topline Phase 4 VOICE data in early 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。